March 27, 2017 — Bracco Diagnostics Inc. announced the launch of its PROTOCO2L TOUCH Colon Insufflator. This device is used to inflate the colon with CO2 in patients who undergo computed tomography colonography (CTC) for the detection of colon cancer.
In the U.S., colon cancer is a leading cause of cancer-related deaths. It is recommended that people age 50 and older be screened for the presence of this disease, as early detection can lead to increased cure rates. Advances in CT imaging have allowed for the examination of the colon via CTC, a quick, non-invasive test that does not require a patient to be sedated.
Due to the increasing evidence of the effectiveness of CTC, the United States Preventative Services Task Force (USPSTF) classified CTC as a Grade A Screening test in June 2016.
The PROTOCO2L TOUCH Colon Insufflator is used in CTC exams to obtain optical distension of the colon. The device utilizes automated insufflation of CO2, which is more rapidly absorbed with less post-procedural discomfort than the alternative, room air. It offers clinicians touch-screen digital technology and other features for procedural efficiency not available from the previous generations of colon insufflators, according to the company.
The device will be displayed at the Bracco Diagnostics Inc. booth at the Society of Abdominal Radiology (SAR) 2017 Annual Scientific Meeting and Education Course, taking place March 26-31, in Hollywood, Fla.
For more information: www.imaging.bracco.com